Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Effects of Giardia intestinalis on mice GI tract (Study ST000332)

Reversed phase POSITIVE ION MODE (Analysis AN000531)

Metabolite	Structure	F1	F2	F3	F4
LPC (22:6)	ME116953	0.84	0.66	2.36	0.31
TG (52:0)	ME117055	0.92	0.84	2.17	0.15
TG (58:8) B	ME117090	2.17	0.31	1.02	0.34
TG (56:8)	ME117082	1.98	0.44	0.85	0.59
TG (58:10)	ME117084	1.84	0.45	0.90	0.72
TG (56:6)	ME117080	2.16	0.44	0.60	0.61
TG (58:9)	ME117091	2.16	0.42	0.75	0.48
TG (58:6)	ME117088	2.25	0.52	0.62	0.36
TG (56:5)	ME117079	2.22	0.57	0.70	0.25
TG (52:4)	ME117059	2.11	0.56	0.79	0.32
TG (54:5)	ME117071	2.14	0.56	0.80	0.27
TG (54:6)	ME117072	2.44	0.40	0.68	0.19
TG (54:7)	ME117073	2.42	0.42	0.69	0.19
TG (56:3)	ME117077	2.23	0.68	0.61	0.17
TG (58:2)	ME117085	2.38	0.57	0.53	0.21
TG (56:2)	ME117076	2.41	0.59	0.51	0.16
TG (58:4)	ME117087	2.41	0.57	0.55	0.15
TG (48:1)	ME117039	2.34	0.55	0.65	0.16
TG (53:1)	ME117062	2.32	0.60	0.56	0.21
TG (60:2)	ME117092	2.30	0.57	0.59	0.25
TG (46:0)	ME117034	1.84	0.86	0.85	0.22
TG (52:1)	ME117056	1.85	0.83	0.83	0.26
TG (52:2)	ME117057	1.82	0.75	0.91	0.34
TG (52:3)	ME117058	1.84	0.71	0.92	0.34
TG (50:1)	ME117046	1.83	0.77	0.86	0.33
TG (54:3)	ME117069	1.86	0.73	0.86	0.35
TG (50:2)	ME117047	1.95	0.66	0.88	0.31
TG (54:4)	ME117070	1.89	0.68	0.88	0.36
TG (56:1)	ME117075	2.01	0.81	0.59	0.32
TG (58:1)	ME117083	2.02	0.73	0.62	0.38
TG (54:1)	ME117067	1.96	0.82	0.72	0.24
TG (54:2)	ME117068	2.08	0.73	0.71	0.22
TG (56:4)	ME117078	2.04	0.72	0.74	0.24
TG (46:2)	ME117036	2.08	0.21	0.18	NA
TG (51:1)	ME117051	2.70	0.38	0.45	0.11
TG (53:2)	ME117063	2.70	0.38	0.44	0.12
TG (48:2)	ME117040	2.65	0.40	0.49	0.11
TG (51:2)	ME117052	2.68	0.35	0.50	0.13
TG (49:2)	ME117044	2.68	0.29	0.55	0.15
TG (51:4)	ME117054	2.70	0.30	0.48	0.18
TG (58:3)	ME117086	2.55	0.47	0.49	0.16
TG (49:1)	ME117043	2.58	0.37	0.57	0.15
TG (50:3)	ME117048	2.56	0.41	0.59	0.12
TG (50:5)	ME117050	2.70	0.36	0.23	0.14
TG (46:1)	ME117035	2.89	0.29	0.38	0.05
TG (55:3)	ME117074	2.95	0.27	0.31	0.06
TG (48:3)	ME117041	2.98	0.24	0.30	0.07
TG (53:4)	ME117065	2.98	0.21	0.31	0.09
TG (50:4)	ME117049	2.91	0.27	0.33	0.10
TG (53:5)	ME117066	2.94	0.22	0.33	0.13
TG (52:6)	ME117061	2.83	0.28	0.32	0.20
TG (53:3)	ME117064	2.78	0.33	0.41	0.11
TG (51:3)	ME117053	2.83	0.27	0.42	0.11
TG (52:5)	ME117060	2.79	0.28	0.43	0.14
SM (d33:1)	ME117018	0.57	1.35	0.16	1.95
PE (34:2)	ME117008	0.72	1.22	0.27	1.81
PC (37:2)	ME116979	0.77	1.20	0.30	1.74
SM (d32:1)	ME117017	0.75	1.25	0.30	1.71
Gal-Gal-Cer(d18:1/16:0) or Lactosylceramide(d18:1/16:0)	ME116946	0.98	1.06	NA	0.97
PC (36:2)	ME116973	0.93	1.05	0.61	1.41
PC (38:7)	ME116989	0.98	1.06	0.54	1.40
DG (40:6)	ME116944	1.01	0.91	0.72	1.40
PC (34:2) A	ME116964	0.94	1.01	0.71	1.35
PC (38:5)	ME116987	0.98	0.98	0.64	1.42
PC (38:4) B	ME116986	1.00	0.99	0.68	1.34
PC (35:2)	ME116969	1.00	0.99	0.65	1.37
PC (40:6)	ME116992	1.02	1.00	0.63	1.35
PC (34:2) B	ME116965	0.93	1.04	0.82	1.22
PC (36:4) A	ME116975	1.03	0.93	0.80	1.27
PC (35:3)	ME116970	1.06	0.96	0.73	1.25
PC (36:3) B	ME116974	1.10	0.92	0.76	1.20
Ceramide (d40:1)	ME116934	1.02	1.04	0.72	1.20
PC (34:3)	ME116966	1.08	1.04	0.63	1.22
PC (36:5)	ME116977	0.92	0.97	0.57	1.57
SM (d34:0)	ME117019	0.99	1.22	0.32	1.41
PE (p-36:2) or PE (o-36:3)	ME117012	1.06	1.05	0.56	1.30
DG (36:4)	ME116941	1.08	1.05	0.50	1.33
SM (d39:1)	ME117026	1.09	1.06	0.49	1.30
PE (p-40:5) or PE (o-40:6)	ME117016	1.06	0.99	0.49	1.44
PE (p-38:4) or PE (o-38:5)	ME117014	1.07	1.06	0.45	1.38
PC (p-42:3) or PC (o-42:4)	ME117005	1.05	1.04	0.50	1.40
SM (d34:1)	ME117020	1.01	1.08	0.49	1.39
PE (38:4)	ME117010	0.96	1.08	0.48	1.47
PE (38:6)	ME117011	0.97	1.04	0.46	1.53
PC (p-38:3) or PC (o-38:4)	ME117002	1.03	1.10	0.33	1.50
PC (p-40:3) or PC (o-40:4)	ME117003	1.04	1.06	0.41	1.47
DG (34:1)	ME116937	1.29	1.02	0.57	1.01
SM (d42:2)	ME117032	1.32	0.95	0.58	1.05
SM (d36:1)	ME117023	1.20	0.95	0.68	1.12
PC (32:0)	ME116958	1.25	0.94	0.69	1.05
PE (p-36:4) or PE (o-36:5)	ME117013	1.23	0.95	0.69	1.07
DG (36:1)	ME116939	1.21	0.98	0.61	1.14
PC (40:8)	ME116994	1.17	0.99	0.64	1.14
SM (d40:0)	ME117027	1.16	1.03	0.63	1.13
PC (p-42:4) or PC (o-42:5)	ME117006	1.25	0.93	0.61	1.15
DG (36:3)	ME116940	1.27	1.00	0.52	1.11
PC (o-32:0)	ME116998	1.27	0.99	0.54	1.11
SM (d40:1)	ME117028	1.25	0.98	0.58	1.11
DG (40:7)	ME116945	1.23	1.00	0.56	1.14
SM (d34:2)	ME117021	1.24	0.98	0.55	1.15
PC (34:0)	ME116963	1.20	1.01	0.53	1.18
PC (o-34:0)	ME116999	1.20	1.03	0.51	1.19
PC (p-34:1) or PC (o-34:2) A	ME117000	1.13	1.03	0.55	1.24
SM (d41:1)	ME117029	1.17	1.03	0.48	1.27
SM (d41:2)	ME117030	1.15	1.04	0.49	1.26
DG (34:2)	ME116938	1.16	0.94	0.55	1.33
DG (38:6)	ME116943	1.16	0.90	0.58	1.35
PC (36:1)	ME116972	1.13	0.93	0.63	1.29
PC (37:4)	ME116981	1.09	0.94	0.68	1.29
PC (38:2)	ME116983	1.15	0.97	0.57	1.28
PC (p-40:5) or PC (o-40:6)	ME117004	1.14	0.97	0.61	1.25
DG (38:5)	ME116942	1.20	0.91	0.62	1.24
SM (d38:1)	ME117025	1.20	0.96	0.57	1.22
PC (37:3)	ME116980	1.10	0.90	0.89	1.10
PC (38:6) A	ME116988	1.05	0.91	0.89	1.16
SM (d36:0)	ME117022	1.18	0.97	0.74	1.06
PE (p-38:5) or PE (o-38:6)	ME117015	1.14	0.99	0.77	1.06
Ceramide (d42:1)	ME116935	1.11	0.99	0.78	1.08
PC (40:5) A	ME116991	1.13	0.98	0.77	1.08
Acylcarnitine C18:0	ME116931	1.14	0.97	0.80	1.04
Ceramide (d42:2)	ME116936	1.13	0.99	0.83	1.02
PC (36:4) B	ME116976	1.18	0.89	0.85	1.06
PC (38:3)	ME116984	1.22	0.85	0.79	1.10
PC (40:7)	ME116993	1.19	0.88	0.76	1.15
PC (35:4)	ME116971	1.34	0.74	0.91	0.98
PC (35:1)	ME116968	1.35	0.79	0.85	0.96
PC (42:7)	ME116997	1.32	0.83	0.86	0.95
PC (32:2)	ME116960	1.38	0.90	0.77	0.86
LPC (20:0)	ME116951	1.30	0.91	0.86	0.85
PC (34:4)	ME116967	1.28	0.89	0.85	0.92
PE (36:1)	ME117009	1.32	0.85	0.61	1.17
PC (32:1)	ME116959	1.42	0.88	0.65	0.95
SM (d42:1)	ME117031	1.37	0.89	0.65	1.00
PC (p-36:1) or PC (o-36:2)	ME117001	1.36	0.82	0.71	1.05
SM (d36:2)	ME117024	1.31	0.87	0.75	1.01
PC (40:4)	ME116990	1.30	0.86	0.69	1.09
PC (p-44:4) or PC (o-44:5)	ME117007	1.31	0.89	0.70	1.04
PC (30:1)	ME116956	1.54	0.94	0.66	0.68
TG (42:1)	ME117033	1.62	0.83	0.49	0.69
TG (58:8) A	ME117089	1.26	0.74	1.02	0.98
LPC (18:0)	ME116948	1.13	0.89	1.11	0.87
PC (36:6)	ME116978	1.16	0.90	0.98	0.94
PC (42:5)	ME116995	1.66	0.66	0.86	0.72
PC (31:0)	ME116957	1.49	0.81	0.87	0.73
PC (37:6)	ME116982	1.39	0.74	0.99	0.84
PC (33:2)	ME116962	1.45	0.71	0.92	0.88
PC (33:1)	ME116961	1.47	0.73	0.96	0.78
PC (42:6)	ME116996	1.47	0.73	0.93	0.81
PC (38:4) A	ME116985	1.50	0.53	0.99	0.96
TG (56:7)	ME117081	1.57	0.59	1.00	0.79
LPC (o-16:0)	ME116954	1.04	1.29	0.70	0.32
LPC (18:2)	ME116950	0.94	1.06	1.02	0.97
LPC (p-16:0) or LPC (o-16:1)	ME116955	0.90	1.20	1.07	0.79
TG (48:0) A	ME117037	0.78	1.23	1.18	0.80
Acylcarnitine C18:2	ME116933	1.25	0.73	1.46	0.64
Acylcarnitine C16:0	ME116930	1.17	0.86	1.22	0.74
Acylcarnitine C18:1	ME116932	1.12	0.81	1.38	0.72
TG (48:0) B	ME117038	1.07	1.12	1.33	0.43
TG (49:0)	ME117042	1.30	0.89	1.34	0.40
LPC (16:0)	ME116947	0.99	0.70	1.78	0.64
LPC (18:1)	ME116949	1.17	0.65	1.71	0.52
LPC (20:4)	ME116952	0.93	0.85	1.58	0.71
TG (50:0)	ME117045	0.74	1.07	1.65	0.60

Factors:

F1	Location:infected distal
F2	Location:infected proximal
F3	Location:uninfected distal
F4	Location:uninfected proximal

Data matrix